Recent SCRS studies of pre- versus post-treatment of anti-PD-1 in basal cell carcinoma have found increased number and clonal expansion of CD39+ CD8+ T cells after immunotherapy49. The gene discussed is ENTPD1; the disease is basal cell carcinoma.